Raptor Pharmaceuticals (RPTP) is gaining Friday after beating analysts' estimates for earnings and revenue in the second quarter and raising its sales guidance for the year.

NEW YORK (TheStreet) -- Raptor Pharmaceuticals (RPTP) was gaining 21.6% to $10.02 Friday after beating analysts' estimates for earnings and revenue in the second quarter and raising its sales guidance for the year.

For the second quarter the drug manufacturer reported a loss of -15 cents a share, beating analysts' estimates of a loss of -21 cents by 6 cents. The company reported revenue of $16.31 million for the quarter, while analysts surveyed by Thomson Reuters expected revenue of $14.58 million for the quarter.

Report Pharmaceuticals also announced that is now expects net products sales of $65 million to $70 million for the full year, up from $55 million to 65 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners.Click here to see the holdings for FREE.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners.Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.